Overview

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

Status:
Terminated
Trial end date:
2019-11-20
Target enrollment:
Participant gender:
Summary
This study evaluates the safety of acalabrutinib and vistusertib when taken in combination.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Acerta Pharma BV
Treatments:
Acalabrutinib